{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:58:55Z","timestamp":1776362335923,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,9,13]],"date-time":"2014-09-13T00:00:00Z","timestamp":1410566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00192-014-2499-2","type":"journal-article","created":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T09:36:36Z","timestamp":1410514596000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events"],"prefix":"10.1007","volume":"26","author":[{"given":"N. F.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. D.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,13]]},"reference":[{"key":"2499_CR1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60:784\u2013795","journal-title":"Eur Urol"},{"key":"2499_CR2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo HC (2011) Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30:1242\u20131248","journal-title":"Neurourol Urodyn"},{"key":"2499_CR3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijcp.12360","volume":"68","author":"G Karsenty","year":"2014","unstructured":"Karsenty G, Baverstock R, Carlson K, Diaz DC, Cruz F et al (2014) Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract 68:731\u2013742","journal-title":"Int J Clin Pract"},{"key":"2499_CR4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00192-013-2246-0","volume":"25","author":"R Ju","year":"2014","unstructured":"Ju R, Garrett J, Wu JM (2014) Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int Urogynecol J 25:479\u2013484","journal-title":"Int Urogynecol J"},{"key":"2499_CR5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2004.10.047","volume":"64","author":"A Tubaro","year":"2004","unstructured":"Tubaro A (2004) Defining overactive bladder: epidemiology and burden of disease. Urology 64:2\u20136","journal-title":"Urology"},{"key":"2499_CR6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","volume":"177","author":"G Karsenty","year":"2007","unstructured":"Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC et al (2007) Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 177:1011\u20131014","journal-title":"J Urol"},{"key":"2499_CR7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","volume":"342","author":"B Schurch","year":"2000","unstructured":"Schurch B, Schmid DM, Stohrer M (2000) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342:665","journal-title":"N Engl J Med"},{"key":"2499_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2499_CR9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1200\/JCO.2008.17.5182","volume":"27","author":"C Dunne","year":"2009","unstructured":"Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:1615\u20131620","journal-title":"J Clin Oncol"},{"key":"2499_CR10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","volume":"127","author":"J Lau","year":"1997","unstructured":"Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820\u2013826","journal-title":"Ann Intern Med"},{"key":"2499_CR11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","volume":"61","author":"RP Manecksha","year":"2012","unstructured":"Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R et al (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61:928\u2013935","journal-title":"Eur Urol"},{"key":"2499_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/nau.20515","volume":"27","author":"F Mascarenhas","year":"2008","unstructured":"Mascarenhas F, Cocuzza M, Gomes CM, Leao N (2008) Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn 27:311\u2013314","journal-title":"Neurourol Urodyn"},{"key":"2499_CR13","first-page":"3291","volume":"13","author":"A Lucioni","year":"2006","unstructured":"Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 13:3291\u20133295","journal-title":"Can J Urol"},{"key":"2499_CR14","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"TA Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder\u2013to include or exclude the trigone? a prospective, randomized, controlled trial. J Urol 184:2423\u20132428","journal-title":"J Urol"},{"key":"2499_CR15","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"2499_CR16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","volume":"139","author":"DD Dykstra","year":"1988","unstructured":"Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919\u2013922","journal-title":"J Urol"},{"key":"2499_CR17","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 185:2229\u20132235","journal-title":"J Urol"},{"key":"2499_CR18","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD (2009) Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 181:2608\u20132615","journal-title":"J Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-014-2499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-014-2499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-014-2499-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T12:32:00Z","timestamp":1717331520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-014-2499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,13]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s00192-014-2499-2","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,13]]}}}